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Abstract
Theautoimmunethyroiddiseases(AITD)arecomplexdiseaseswhicharecausedbyaninteractionbetweensusceptibilitygenes
andenvironmentaltriggers.Geneticsusceptibilityincombinationwithexternalfactors(e.g.dietaryiodine)isbelievedtoinitiate
the autoimmune response to thyroid antigens. Abundant epidemiological data, including family and twin studies, point to a
stronggeneticinﬂuenceonthedevelopmentofAITD.Varioustechniqueshavebeenemployedtoidentifythegenescontributing
to the etiology of AITD, including candidate gene analysis and whole genome screening. These studies have enabled the
identiﬁcationofseveralloci(geneticregions)thatarelinkedwithAITD,andinsomeoftheseloci,putativeAITDsusceptibility
genes have been identiﬁed. Some of these genes/loci are unique to Graves’disease (GD) and Hashimoto’s thyroiditis (HT) and
some are common to both the diseases, indicating that there is a shared genetic susceptibility to GD and HT. The putative GD
andHTsusceptibilitygenesincludebothimmunemodifyinggenes(e.g.HLA,CTLA-4)andthyroidspeciﬁcgenes(e.g.TSHR,
Tg). Most likely, these loci interact and their interactions may inﬂuence disease phenotype and severity.
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Introduction
The autoimmune thyroid diseases (AITD) include a
number of conditions which have in common cellular
and humoral immune responses targeted at the thyroid
gland. The AITD include Graves’ disease (GD) and
Hashimoto’s thyroiditis (HT), both of which are
characterized by inﬁltration of the thyroid by Tand B
cells reactive with thyroid antigens, production of
thyroid autoantibodies, with the resultant clinical
manifestations (hyperthyroidism in GD and hypo-
thyroidism in HT) (reviewed in Weetman (1996) and
Davies(2000)).Thereisabundantevidenceforamajor
genetic inﬂuence on the development of AITD
(reviewed in Tomer et al. (1997a) and Brix et al.
(1998a)).Therefore,thecurrentparadigmisthatAITD
are complex diseases in which susceptibility genes and
environmental triggers act in concert to initiate the
autoimmune response to the thyroid. In this review, we
focusonthegenesalreadyfoundtocontributetoAITD.
While the proof that a gene causes AITD requires
functional studies, the genes we will discuss are
strong candidates, and their functions are now being
investigated. We will not discuss in detail the genetic
regions linked with AITD in which no candidate gene
has yet been identiﬁed.
Genetic epidemiology of AITD
The familial occurrence of AITD has been reported
by investigators for many years. Early studies showing
familial aggregation of AITD were mostly obser-
vational, based on careful family histories from
patients (Bartels 1941, Martin 1945). Later, in the
1960s, Hall and Stanbury (1967) showed that 33% of
siblings of patients with GD or HT developed AITD
themselves. Additionally, they found that 56% of
siblings of AITD patients had thyroid antibodies
(TAbs) (Hall and Stanbury 1967). A recent survey by
our own group revealed that 41/114 (36%) of GD
patients with ophthalmopathy reported a family
history of AITD and 26/114 (23%) had a ﬁrst degree
relative with AITD (Villanueva et al. 2000).
The sibling risk ratio (ls), which is the ratio of the
prevalence of the disease in siblings of affected
individuals compared to the prevalence of the disease
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a good estimate of disease heritability, with ls . 5
considered signiﬁcant. The ls in AITD has been
estimated to be between 5.9 (Brix et al. 1998a) and
.10 in AITD (Vyse and Todd 1996, Villanueva et al.
2000), supporting a strong genetic inﬂuence on the
development of AITD.
Several large twin studies have been reported from
Denmark showing a higher concordance of GD in
monozygotic (MZ) twins when compared to dizygotic
(DZ) twins (Brix et al. 1998b, Brix et al. 2001).
A recent GD twin study from California conﬁrmed the
Danish twin study results (Ringold et al. 2002). Twin
studies in HT have also shown a higher concordance
rate in MZ compared to DZ twins (Brix et al. 2000).
The concordance rates for TAbs were also reported to
be higher in MZ twins compared to DZ twins (Phillips
et al. 2002). Thus, the twin data conﬁrm the presence
of a substantial inherited susceptibility to AITD.
Susceptibility genes in AITD
Immune related genes
The human leukocyte antigen (HLA) gene (Table I). The
major histocompatibility complex (MHC) region,
encoding the HLA glycoproteins, consists of a
complex of genes located on chromosome 6p21
(Todd et al. 1988). GD was initially found to be
associated with HLA-B8 in Caucasians (Bech et al.
1977, Farid et al. 1980). Subsequently, it was found
that GD was more strongly associated with HLA-
DR3, which is now known to be in linkage
disequilibrium with HLA-B8 (reviewed in Farid
(1981)). The frequency of DR3 in GD patients was
generally 40–55% and in the general population
,15–30% giving a RR for people with HLA-DR3 of
up to 4.0 (Farid et al. 1979, Farid et al. 1980, Volpe
1990, Mangklabruks et al. 1991). A recent family-
based study from UK using the transmission
disequilibrium test (TDT) conﬁrmed the results of
the case control studies (Heward et al. 1998a). Among
Caucasians, HLA-DQA1*0501 was also shown to be
associated with GD ðRR ¼ 3:8Þ (Yanagawa et al.
1993, Barlow et al. 1996, Marga et al. 2001), but
recent studies have suggested that the primary
susceptibility allele in GD is indeed HLA-DR3
(HLA-DRB1*03) (Zamani et al. 2000). However,
the exact amino-acid sequence in the DRb1 chain
conferring susceptibility to GD is unknown. In other
autoimmune diseases including Type 1 diabetes
(T1D) (Todd et al. 1987), there is persuasive
evidence that the disease is associated with speciﬁc
amino-acid sequences of the DRB1 and DQ genes. We
recently sequenced the HLA-DRB1 locus in a
population of GD patients and controls (Ban et al.
2004a). Sequence analysis showed an increased
frequency of arginine at position 74 of the HLA-
DRb1 chain (DRb-Arg-74) in GD patients compared
to controls (Ban et al. 2004a). Moreover, subset
analyses showed that DRb-Arg-74 was also
signiﬁcantly more frequent in the HLA-DR3
negative GD patients than in controls, suggesting
that the association with DRb-Arg-74 is independent
of the association with HLA-DR3. The pattern of
transmission of HLA alleles from parents to offspring
was also studied. A recent study suggested a
preferential transmission of HLA susceptibility
alleles from fathers to affected offspring, whereas
maternal susceptibility alleles were not transmitted
Table I. Some HLA association studies in GD performed in Caucasians.
Country No. of patients HLA allele Relative risk/p-value Reference
Belgium 194 DRB1*0301 2.53 Zamani et al. (2000)
Canada 175 B8 3.1 Farid et al. (1980)
DR3 5.7
Denmark 86 B8 2.80 Bech et al. (1977)
Dw3 3.94
Germany 253 DR3 2.52 Schleusener et al. (1989)
Hungary 256 B8 3.48 Stenszky et al. (1985)
DR3 4.8
Sweden 78 B8 4.4 Dahlberg et al. (1981)
DR3 3.9
UK 127 B8 2.77 Kendall-Taylor et al. (1988)
DR3 2.13
UK 101 DR3 1.10 Weetman et al. (1988)
USA 65 DR3 3.38 Mangklabruks et al. (1991)
USA 92 DRB1*03 2.6 Chen et al. (1999)
DRB1*08 3.2
UK 120 DQA1*0501 3.8 Barlow et al. (1996)
UK 228 DRB1*0304 2.7 Heward et al. (1998a)
DQB1*0301 1.9
DQA1*0501 3.2
USA 94 DQA1*0501 3.71 Yanagawa et al. (1993)
Y. Ban & Y. Tomer 48more frequently than expected (Segni et al. 2002).
This may suggest parental imprinting in the
transmission of HLA susceptibility alleles to affected
offspring.
Data on HLA haplotypes in HT have been less
deﬁnitive than in GD. Initial studies failed to
demonstrate an association between goitrous HT and
HLA A- B- or C- antigens (Irvine et al. 1978). Later
studies showed an association of goitrous HT with
HLA- DR5 ðRR ¼ 3:1Þ (Farid et al. 1981) and of
atrophicHTwithDR3ðRR ¼ 5:1Þ(Moensetal.1978).
The association of HT with HLA-DR4 in Caucasians
hasbeenconﬁrmedinsubsequentstudies(Tandonetal.
1991, Ban et al. 2002a), and further supported by
studies of transgenic mice (Kong et al. 1996).
An association between HT and HLA-DQw7
(DQB1*0301) has also been reported in Caucasians
(Badenhoop et al. 1990, Wu et al. 1994).
Linkage studies of HLA in AITD have been largely
negative (Bode et al. 1973, Roman et al. 1992,
Barbesino et al. 1998). Only one recent study from
UK showed weak evidence for linkage between GD
and the HLA region (Vaidya et al. 1999a), and an
additional study reported linkage only when con-
ditioning on DR3 (Shields et al. 1994). It is difﬁcult to
explain why the HLA genes show consistent associ-
ation with GD but no evidence for linkage. The most
likely explanation is that HLA is a modulating gene for
AITD but not a primary susceptibility gene.
The cytotoxic T lymphocyte antigen-4 (CTLA-4) immune
regulatory cluster on chromosome 2q33 (Table II).
Co-stimulatory molecules are critical to the
activation of T cells by antigen presenting cells
(APCs). APCs activate T cells by presenting to the
T cell receptor an antigenic peptide bound to an HLA
class II protein on the cell surface. However, a second
signal is also required for T cell activation and these
co-stimulatory signals may be provided by the APCs
themselves or other local cells (Reiser and Stadecker,
1996). The co-stimulatory signals are provided by a
variety of proteins which are expressed on APCs (e.g.
B7-1, B7-2, B7h, CD-40) and interact with receptors
(CD28, CTLA-4, and CD-40L) on the surface of
CD4þT-lymphocytes during antigen presentation
(Reiser and Stadecker, 1996). Whereas, the binding
of B7 to CD28 on T cells co-stimulates T cell
activation, the presence of CTLA-4, which has a
higher afﬁnity for B7, down regulates T-cell activation
by competing for the binding of B7 to CD28. A new
member of this family of co-stimulatory molecules,
inducible co-stimulator (ICOS) was identiﬁed by
Hutloff et al. (1999). Unlike the constitutively
expressed CD28, ICOS is induced on the T-cell
surface and does not upregulate the production of
interleukin (IL)-2, but induces the synthesis of IL-4
(Coyle et al. 2000). Interestingly, CD28, CTLA-4 and
ICOS form a gene cluster in a 300kb region on
chromosome 2q33. Thus, associations of
autoimmune diseases with this region may represent
the effects of any of these three genes alone or in
combination due to linkage disequilibrium.
Recently, there have been several reports demon-
strating an association between CTLA-4 gene poly-
morphisms and AITDs, both GD and HT (Yanagawa
et al. 1995, Nistico et al. 1996, Donner et al. 1997a,b,
Kotsa et al. 1997a,Marron et al. 1997, Yanagawaet al.
1997, Braun et al. 1998, Heward et al. 1998b, 1999a,
Petrone et al. 2001, Tomer 2001, Kouki et al. 2002,
Nithiyananthan et al. 2002).
Since CTLA-4 is a non speciﬁc co-stimulatory
molecule, it is expected to confer susceptibility to
AITD and autoimmunity in general, and not
Table II. Some CTLA-4 association studies in autoimmune thyroid diseases in Caucasians and non-Caucasian population.
CTLA-4 polymorphism Country Ethnic group Dis. No. RR*/P value Reference
CTLA-4(AT) USA Caucasians GD 133 2.82 Yanagawa et al. (1995)
CTLA-4(AT) UK Caucasians GD 112 2.1 Kotsa et al. (1997a)
HT 44 2.2
CTLA-4(AT) Hong-Kong Chinese GD 94 p ¼ 0:037 Nistico et al. (1996)
CTLA-4(AT) Japan Japanese GD þ HT 349 1.8 Volpe (1990)
Thr/Ala (A/G)49 Germany Caucasians GD 305 2.0 Donner et al. (1997a)
Thr/Ala (A/G)49 UK Caucasians GD 94 p ¼ 0:003 Vaidya et al. (1999b)
Thr/Ala (A/G)49 UK Caucasians GD 379 1.6 Heward et al. (1999a)
Thr/Ala (A/G)49 UK Caucasians GD 484 p , 0:0001 Allahabadia et al. (2001)
Thr/Ala (A/G)49 USA Caucasians GD 85 1.6 Villanueva et al. (2000)
Thr/Ala (A/G)49 Germany Caucasians HT 73 p , 0:04 Donner et al. (1997b)
Thr/Ala (A/G)49 Italy Caucasians HT 126 NS* Petrone et al. (2001)
Thr/Ala (A/G)49 UK Caucasians HT 158 1.57 Nithiyananthan et al. (2002)
Thr/Ala (A/G)49 Slovenia Caucasians TAb’s 67 p , 0:005 Zaletel et al. (2002)
Thr/Ala (A/G)49 Japan Japanese GD 153 2.64 Yanagawa et al. (1997)
Thr/Ala (A/G)49 Korea Korean GD 97 1.6 Park et al. (2000)
HT 110 NS
*RR, relative risk; NS, not signiﬁcant.
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was reported to be associated and linked with all forms
of AITD (GD, HT, and TAbs, see below), and with
many autoimmune diseases such as Type 1 diabetes
(T1D) (Nistico et al. 1996, Donner et al. 1997a,
Marron et al. 1997, Ueda et al. 2003), Addison’s
disease (Vaidya et al. 2000), and myasthenia gravis
(Huang et al. 1998).
Two studies have now shown that CTLA-4 confers
susceptibility to the production of TAbs. Our group
has shown strong evidence for linkage between the
CTLA-4 gene region and the production of TAbs with
a maximum LOD score (MLS) of 4.2 (Tomer et al.
2001). Recently, another report has described an
association between the G allele of the CTLA-4 A/G49
SNP and thyroid autoantibody diathesis (Zaletel et al.
2002). Since the development of TAbs
often represents the pre-clinical stage of AITD
(Vanderpump et al. 1995), it is possible that
CTLA-4 predisposes non-speciﬁcally to the develop-
ment of thyroid autoimmunity. Additional genetic
and/or environmental factors must be necessary for
the development of the speciﬁc GD/HT phenotypes
(Tomer 2001).
As mentioned, the region on chromosome 2q33
containing the CTLA-4 gene harbors in addition the
CD28 and ICOS genes and it was unclear whether the
CTLA-4 gene itself or another immune regulatory
gene in the region was involved in the genetic
susceptibility to AITD. Recently, we tested additional
genes and markers in the 2q33 region, and the
strongest association was with the CTLA-4 markers
(Tomer et al. 2001). These results were in agreement
with results obtained in T1DM (Marron et al. 2000,
Wood et al. 2002). More recently, Ueda et al. (2003)
also showed that CTLA-4 was indeed the AITD
susceptibility gene in this region. They identiﬁed a
new 30 untranslated region SNP that was strongly
associated with AITD.
The CD40 gene. Two linkage studies, one by our group
(Tomer et al. 1998) and one by Pearce et al. (1999)
have shown evidence that a locus on 20q11 was linked
with GD. This GD locus was not linked to HT, since
analysis of the data for the HT families gave strongly
negative LOD scores. Moreover, in families with GD-
and HT-affected individuals, the locus was linked only
with GD, demonstrating its high speciﬁcity for GD
(Tomer et al. 1998, Wood et al. 2002). The CD40
gene, an important regulator of B cell function, is
located within the linked region on chromosome
20q11 and, therefore, it was a likely positional
candidate gene for GD. CD40 is a transmembrane
glycoprotein that is expressed predominantly on B
cells, and also on monocytes, dendritic cells, epithelial
cells and other cells (reviewed in Durie et al. (1994)).
It is a member of the tumor necrosis factor receptor
superfamily and it binds to a ligand (CD40L or
CD154), which is expressed mainly on activated T
cells. Binding of CD40L to CD40 induces B cells to
proliferate and undergo immunoglobulin isotype
switching (Banchereau et al. 1994). CD40 has been
shown to play an important role in the regulation of
humoral immunity, central and peripheral T-cell
tolerance, and APC function (reviewed in Foy et al.
(1996)). Moreover, in vivo blockade of CD40 has
been shown to suppress the induction of experimental
autoimmune thyroiditis (Carayanniotis et al. 1997).
Therefore, we tested whether CD40 was the GD
susceptibility gene on chromosome 20q11.
Sequencing of the CD40 gene revealed a C/T SNP
in the 50 untranslated region (50 UTR) of the gene.
Analysis of the CD40 50 UTR SNP in 154 Caucasian
GD patients and 118 Caucasian controls showed an
association between the CC genotype and GD but
with a low relative risk of 1.6 (Tomer et al. 2002a).
TDTanalysis also showed preferential transmission of
the C allele of the CD40 50 UTR SNP to affected
individuals (Tomer et al. 2002a). Other investigators
who found evidence for linkage in this region have not
found an association between this SNP and GD in
their dataset (Pearce, personal communication) and it
is possible that other polymorphisms in the CD40
gene, or another gene in linkage disequilibrium with
CD40, is the GD susceptibility gene.
Other immune related genes. Other immune related
genes tested for association with GD include the T cell
receptor b chain (Demaine et al. 1987, Weetman et al.
1987, Mangklabruks et al. 1991), the IgG heavy chain
(IgH) gene (Roman et al. 1989, Fakhfakh et al. 1999),
the IL-1 receptor antagonist gene (Blakemore et al.
1995, Cuddihy and Bahn 1996, Muhlberg et al. 1998,
Hewardetal.1999b),tumor necrosisfactora(TNFa)
gene (Barbesino et al. 1998), interferon g gene
(Siegmund et al. 1998), the transporters associated
with antigen presentation (TAP) genes (Rau et al.
1997), and the IL-4 gene (Heward et al. 2001).
However, none of these have produced replicable
associations with GD. The vitamin D binding protein,
which may have some immune modulatory functions,
has also been reported to be associated with GD (Pani
et al. 2002).
Thyroid associated genes
The thyroglobulin (Tg) gene
Two studies havefound evidence for linkage between a
locus on chromosome 8q24 and AITD. Our group has
shown strong evidence for linkage at the Tg gene locus
with an MLS of 3.5 between D8S514 and D8S284
(Tomer et al. 2002b). Recently, another study in
Japanese sib-pairs identiﬁed a major AITD locus on
8q24 very close to the locus, which we identiﬁed
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within this linked region we proceeded to analyze the
Tg gene directly. We identiﬁed two new Tg micro-
satellites in intron 10 (designated Tgms1) and intron
27 (designated Tgms2). Linkage analysis using
Tgms2 gave a 2-point LOD score of 2.1 and a
multipoint LOD score of 2.9, conﬁrming that it was
the Tg gene linked with AITD (Tomer et al. 2002b).
We then used the same two Tg microsatellites to test
whether the Tg gene was associated as well as linked
with AITD. Using an unselected group of 190
Caucasian GD patients and 134 age- and sex-matched
Caucasian controls we found only a weak association
between Tgms2 and AITD (p ¼ 0:05; RR ¼ 1:4)
(Tomer et al. 2002b). However, the association was
more impressive when the probands from the linked
families ðn ¼ 32Þ were used (p ¼ 0:004; RR ¼ 2:3).
TDT analysis also showed an association of Tgms2
with AITD (p ¼ 0:02; Table III), but with a different
allele, suggesting that Tgms2 was in linkage disequili-
brium with another polymorphism of the Tg gene.
These results have been replicated recently in a UK
dataset (Collins et al. 2003). As in our study, the UK
study also showed a signiﬁcant association between
Tgms2 and AITD (p , 0:001). Moreover, the same
Tgms2allelethatwefoundtobeassociatedwithAITD
was found to be associated by Collins et al. (2003).
Thus, the Tg gene was both linked and associated with
AITD and, therefore, is an important AITD suscep-
tibilitygene.Recently,sequencechangesintheTggene
whichwereassociatedwith AITDwereidentiﬁed (Ban
et al. 2003). Case control association studies for 14 Tg
SNPs in AITD patients and controls showed that one
SNP cluster (in exons 10–12) and an exon 33 SNP
were signiﬁcantly associated with AITD (Ban et al.
2003). However, it remains possible that another gene
on 8q24 in linkage disequilibrium with Tg was the
AITD susceptibility gene responsible for the observed
linkage and association at this locus.
The TSH receptor (TSHR) gene
The hallmark of GD is the production of the TSHR
antibodies. Therefore, the TSHR gene was thought to
be a likely candidate gene for GD. Three common
germline SNPs of the TSHR have been described
(Tonacchera and Pinchera 2000). Two of them are
located in the extracellular domain of the TSHR: an
aspartic acid to histidine substitution at position 36
(D36H), and a proline to threonine substitution at
position 52 (P52T). The third SNP is a substitution of
glutamic acid for aspartic acid (D727E) within the
intracellular domain of the receptor. Most studies on
the contribution of the TSHR gene to the genetic
susceptibility to GD have focused on the two SNPs in
the extracellular domain of the TSHR (Cuddihy et al.
1995, Kotsa et al. 1997b, Allahabadia et al. 1998,
Simanainen et al. 1999, Chistyakov et al. 2000,
Kaczur et al. 2000), because this domain is the major
site for TSH and TSHR antibody binding. Amino
acid changes in the extracellular domain of the TSHR
could theoretically change the amino acid sequence of
TSHR T-cell epitopes (Rapoport et al. 1998). Initial
studies suggested that the P52T SNP was associated
with GD in females (Cuddihy et al. 1995). However,
other authors were unable to conﬁrm the association
between the P52T SNP and GD in Caucasians (Kotsa
et al. 1997b, Allahabadia et al. 1998, Simanainen et al.
1999, Chistyakovet al. 2000, Kaczur et al. 2000). The
D36H SNP has also been reported not to be
associated with GD (Simanainen et al. 1999). Linkage
studies in GD families using three microsatellite
markerswithin introns 2 and 7 of the TSHR gene were
also negative in Caucasians (De Roux et al. 1996,
Tomer et al. 1999). Recently, the D727E SNP was
reported to be associated with GD in a Caucasian
Russian population (Chistiakov et al. 2002), but these
results were not replicated in a subsequent study
(Muhlberg et al. 2000). Recently, we also tested
whether the D727E SNP was associated with GD, but
there was no association between the D727E SNP and
GD, and no effect of the D727E SNP on the GD
phenotype or disease severity was seen (Ban et al.
2002b). In addition, the frequency of the G allele was
not increased in patients with more severe forms of
GD (i.e. ophthalmopathy and goiter) and in patients
with early disease onset. Our own study and other
negative TSHR studies have not excluded a weak
association between GD and the TSHR gene since
very large datasets may be needed to detect
associations with low RRs. We, therefore, performed
a meta-analysis combining our data with the data
reported in the previous two negative TSHR studies.
The results showed a weak association between the
D727E SNP E allele and GD (p ¼ 0:03; RR ¼ 1:6)
(Ban et al. 2002b). Therefore, at this time it remains
possible that the TSHR is a minor susceptibility gene
for GD.
Table III. Transmission disequilibrium test for markers D8S284,
Tgms1 and Tgms2 in 102 AITD families.
Marker
Allele/
Haplotype Transmitted Untransmitted p-value
D8S284 3 54 34 0.03
96 1 6 0.03
All others 111 121 NS*
Tgms2 3 48 34 NS
41 4 4 0.02
73 2 5 2 0.02
All others 62 66 NS
D8S284/
Tgms1
3/3 32 12 0.002
All others 101 121 NS
*NS, not signiﬁcant; Tgms1, microsatellite marker located in intron
10 of the Tg gene; Tgms2, microsatellite marker located in intron 27
of the Tg gene.
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The TPO gene was tested for linkage and association
with AITD in two studies using a microsatellite inside
the TPO gene. However, these studies showed no
evidence of linkage and/or association of the TPO
gene with AITD (Pirro et al. 1995, Tomer et al.
1997b). Therefore, the TPO gene is most likely not a
major susceptibility gene for AITD.
The effect of ethnicity in the development
of AITD
The HLA gene (Table IV)
Aspreviouslymentioned,HLA-DR3isassociatedwith
GDinCaucasians.TheHLAgeneswerealsoshownto
be associated with GD in non-Caucasians, albeit the
associated alleles were different (Table IV). Studies in
the Japanese population have shown associations of
GD with HLA-B35 (Kawa et al. 1977, Inoue et al.
1992). However, other class I and II HLA alleles have
also been reported to be increased in Japanese GD
patients (Katsuren et al. 1994, Onuma et al. 1994,
Ohtsuka and Nakamura 1998). In Chinese an
increased frequency of HLA-Bw46 has been reported
(Chan et al. 1978, Tan et al. 1988, Yeo et al. 1989,
Chan et al. 1993, Cavan et al. 1994). It is interesting
that in Asians the HLA associations are with class I
genes while in Caucasians they are with class II genes.
This may imply that other non-HLA genes in the
region in linkage disequilibrium with class I genes are
the susceptibility genes in Asians. In contrast, DR3 is
believed to be the causative gene in Caucasians (see
below). In African–Americans an increased frequency
of HLA DRB3*0202 has been reported (Table IV)
(Chenetal.2000a).Interestingly,onestudyofamixed
population in Brazil showed association with HLA-
DR3 implying that this allele may confer susceptibility
in otherethnic groups and not just Caucasians (Maciel
et al. 2001). Alternatively, this Brazilian population
may have been mostly of European ancestry.
Also, HLA association studies in HT have not been
consistent in non-Caucasian ethnic groups, e.g. HLA-
DRw53 in Japanese (Honda et al. 1989), and HLA-
DR9 in Chinese (Hawkins et al. 1987) (Table IV).
Inaddition,linkagestudiesofHLAinAITDhavebeen
consistently negative in non-Caucasians, including
Chinese (Hawkins et al. 1985a) and Japanese (Sakai
et al. 2001). The negative linkage studies imply that
HLA are also minor AITD genes in non-Caucasians.
The CTLA-4 gene
The association between GD and the CTLA-4 30 UTR
microsatellite and A/G49 SNP has been consistent
acrosspopulationsofdifferentethnicbackgroundssuch
asJapanese(Yanagawaetal.1997,Akamizuetal.2000),
and Koreans (Park et al. 2000). As was reported in
Caucasians(Hewardetal.1998b),the C/T2318 SNPof
CTLA-4 has not been associated with GD in Chinese
(Hewardetal.1998b).Ithasalsobeenreportedthatthe
frequency of the G allele and the GG genotype of
the CTLA-4 A/G49 SNP was signiﬁcantly higher in
GD patients who did not go into remission after ﬁve
years on anti-thyroid medications in Japanese (Kinjo
etal.2002).Similarly,CTLA-4hasbeenreportedtobe
associated with HT in non-Caucasians including
Japanese (Akamizu et al. 2000, Sale et al. 1997).
Table IV. Some HLA association studies in AITD performed in non-Caucasian populations.
Country Ethnic group Dis. No. of Patients HLA allele(s) RR*/p-value Reference
Hong Kong Chinese GD 132 Bw46 4.8 Hawkins et al. (1985b)
Hong Kong Chinese GD 97 B46 2.3 Cavan et al. (1994)
DR9 2.2
DQB1*0303 3.2
Singapore Chinese GD 35 B46 8.2 Chan et al. (1993)
Singapore Chinese GD 159 Bw46 4.2 Yeo et al. (1989)
Japan Japanese GD 33 Bw35 p , 0:02 Kawa et al. (1977)
Japan Japanese GD 106 B46 p , 0:000 Onuma et al. (1994)
Japan Japanese GD 76 A2 2.86 Dong et al. (1992)
DPB1*0501 5.32
Korea Korean GD 128 B13 3.8 Cho et al. (1987)
DR5 4.4
DRw8 2.3
India Asian GD 57 B8 4.1 Tandon et al. (1990)
Indian DQw2 5.4
USA African–American GD 73 No association Sridama et al. (1987)
USA African–American GD 49 DRB3*0202 3.6 Chen et al. (2000b)
South Africa African GD 103 DR1 3.5 Omar et al. (1990)
DR3 2.4
China Chinese HT 53 DRw9 p , 0:05 Hawkins et al. (1987)
Japan Japanese HT 99 DRw53 3.33 Honda et al. (1989)
*RR, relative risk.
Y. Ban & Y. Tomer 52Although no linkage study has been reported in non-
Caucasians, the association of CTLA-4 across popu-
lationsofdifferentethnicbackgroundsshowsthatitisan
importantsusceptibilitygenefor thyroidautoimmunity.
Other immune related genes
The IgH gene was found to be associated with GD in
the Japanese (Nakao et al. 1980, Nagataki, 1986).
However, these results have not been reproduced in
Caucasians (Roman et al. 1989, Fakhfakh et al. 1999).
This might imply that the IgH gene may contribute to
the susceptibility to GD only in the Japanese if a
founder effect exists. Alternatively, these could result
from random event due to sampling small popu-
lations. Recently, the TNF a gene (Kamizono et al.
2000) and the vitamin D receptor, which may have
some immune modulatory functions, has been
reported to be associated with GD in Japanese (Ban
et al. 2000). A C/T SNP in the promoter region of the
CD40 gene has also been reported to be associated
with GD in Koreans (Kim et al. 2003). These results
need to be conﬁrmed and it cannot be excluded that
other genes in linkage disequilibrium with these genes
arethesusceptibilitygenesattheseloci.Otherimmune
related genes such as the interferon g gene have not
been tested yet in non-Caucasians, and warrant
further studies.
The Tg gene
A Japanese whole genome screen in 123 Japanese sib-
pair families identiﬁed two loci giving strong evidence
for linkage [i.e. MLS . 2:0]. One of these loci is
located on chromosome 8q24 and showed evidence
for linkage with both AITD ðMLS ¼ 2:31Þ and HT
ðMLS ¼ 3:77Þ (Sakai et al. 2001). This locus is
identical to the one found to be linked in Caucasians
(Tomer et al. 2002b) and contains the Tg gene. Since
t h eT gl o c u sw a sl i n k e dw i t hA I T Db o t hi n
Caucasians and in Japanese, this supports that it is a
major gene. Indeed, Tgms2 was associated with HT in
Japanese ðp ¼ 0:04Þ (Ban et al. 2004b). However,
since the signiﬁcance was borderline, this association
could still be due to random chance event.
The TSHR gene
Associations between AITD and TSHR microsatellite
markers have been reported in the Japanese (Sale et al.
1997, Akamizu et al. 2000). However, these results
have not been reproduced in Caucasians (Kotsa et al.
1997b, Allahabadia et al. 1998, Simanainen et al.
1999, Chistyakov et al. 2000, Kaczur et al. 2000,
Villanueva et al. 2000). These results suggest that
TSHR gene may contribute to the susceptibility to
GD only in Japanese especially if there is a founder
effect. For example, NOD2 mutations in Crohn’s
disease were shown only in Caucasians, and not in
Japanese (Yamazaki et al. 2002).
Conclusion
The AITD are complex diseases believed to be caused
by the combined effects of multiple susceptibility
genes and environmental triggers. There are sufﬁcient
epidemiologic data to support an important genetic
contribution to the development of AITD, and in the
past few years several loci and genes have shown
evidence for linkage and/or association with AITD.
The genetic susceptibility to AITD seems to involve
several genes with varying effects. With the com-
pletion of the human genome project and
the establishment of large SNP databases the
identiﬁcation of additional AITD susceptibility genes
will become more feasible.
The AITD loci identiﬁed so far show that some
putative AITD susceptibility genes may be immune
related genes which increase the susceptibility to
autoimmunity in general (e.g. HLA, CTLA-4) while
others may be speciﬁc to AITD (e.g. TSHR, Tg). The
next step in investigating the role of these genes in the
development of AITD is by functional studies and
genotype–phenotype correlations. Preliminary func-
tional studies have been performed for HLA (Sawai
and DeGroot 2000) and CTLA-4 (Kouki et al. 2000,
Xu et al. 2002). More functional studies are needed
for these and other genes which have shown
association with AITD.
It is most likely that the susceptibility genes for
AITD interact and that their interactions may
inﬂuence disease phenotype and severity (Tomer
et al. 1999). The molecular basis for the interactions
between susceptibility genes in complex diseases is
unknown. These interactions could represent the
cumulative effect of increased statistical risk, or
alternatively, there may be molecular interactions
between the susceptibility genes or their products
which ultimately determine disease phenotype. We are
slowly progressing towards identiﬁcation of the AITD
susceptibility genes and once they are identiﬁed, we
will begin to understand the underlying molecular
mechanisms by which they induce thyroid
autoimmunity.
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